BWP
PRVB

Baldwin Wealth Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Baldwin Wealth Partners’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,000
Closed -$83K – 562
2020
Q1 		$83K Buy
+9,000
New +$116K 0.01% 220

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baldwin Wealth Partners's PRVB Position: Q2 2020 in Review

Baldwin Wealth Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2020, closing a stake of 9,000 shares — an estimated $83K sold.

Baldwin Wealth Partners first reported a position in PRVB in Q1 2020 and held it in 1 quarter. The position peaked at $83K in Q1 2020. 106 funds tracked by Wall St. Rank hold PRVB as of Q2 2020.

  • Baldwin Wealth Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Baldwin Wealth Partners sold 9,000 Provention Bio, Inc. Common Stock shares in Q2 2020, an estimated $83K.
  • Baldwin Wealth Partners first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Baldwin Wealth Partners's Provention Bio, Inc. Common Stock position peaked at $83K in Q1 2020.
  • 106 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2020.

Based on Baldwin Wealth Partners's 13F filing for Q2 2020, filed 21 Jul 2020.